{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:28:00Z","timestamp":1792794480258,"version":"4.5.0"},"reference-count":129,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministry of Education, University and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy","id":[{"id":"https:\/\/ror.org\/04jr1s763","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale for Review<\/jats:title>\n                    <jats:p>We performed a systematic review of the literature to investigate the efficacy and safety of pentamidine isethionate for the treatment of human tegumentary and visceral leishmaniasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>A total of 616 papers were evaluated, and 88 studies reporting data on 3108 cases of leishmaniasis (2082 patients with tegumentary leishmaniasis and 1026 with visceral leishmaniasis) were finally included. The majority of available studies were on New World cutaneous leishmaniasis and visceral leishmaniasis caused by Leishmania donovani. At the same time, few data are available for Old World cutaneous leishmaniasis, mucosal leishmaniasis, and visceral leishmaniasis caused by L. infantum. Pooled cure rate for tegumentary leishmaniasis was 78.8% (CI 95%, 76.9\u201380.6%) and 92.7% (CI 95%, 88.3\u201397.1%) according to controlled randomized trial and observational studies and case report and case series respectively. Pooled cure rate for visceral leishmaniasis was 84.8% (CI 95%, 82.6\u201387.1%) and 90.7% (CI 95%, 84.1\u201397.3%) according to controlled randomized trial and observational studies and case report and case series, respectively. Comparable cure rate was observed in recurrent and refractory cases of visceral leishmaniasis. Concerning the safety profile, among about 2000 treated subjects with some available information, the most relevant side effects were six cases of arrhythmia (including four cases of fatal ventricular fibrillation), 20 cases of irreversible diabetes, 26 cases of muscular aseptic abscess following intramuscular administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/recommendations<\/jats:title>\n                    <jats:p>Pentamidine isethionate is associated with a similar cure rate of the first-line anti-leishmanial drugs. Severe and irreversible adverse effect appear to be rare. The drug may still have a role in the treatment of any form of human leishmaniasis when the first-line option has failed or in patients who cannot tolerate other drugs also in the setting of travel medicine. In difficult cases, the drug can also be considered as a component of a combination treatment regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jtm\/taab065","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T21:20:21Z","timestamp":1619040021000},"source":"Crossref","is-referenced-by-count":47,"title":["Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review"],"prefix":"10.1093","volume":"28","author":[{"given":"Matteo","family":"Piccica","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Careggi, largo Brambilla 3, Firenze (FI), Florence 50134, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bartoloni","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy"},{"name":"Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Careggi, largo Brambilla 3, Firenze (FI), Florence 50134, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Zammarchi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy"},{"name":"Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Careggi, largo Brambilla 3, Firenze (FI), Florence 50134, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"2021121413563052400_ref1","first-page":"22","volume-title":"Control of the leishmaniases","author":"Committee WHOE","year":"2010"},{"key":"2021121413563052400_ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Bern","year":"2012","journal-title":"PLoS One"},{"key":"2021121413563052400_ref3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0035-9203(86)90243-9","article-title":"Mucosal leishmaniasis (\u201cespundia\u201d Escomel, 1911)","volume":"80","author":"Marsden","year":"1986","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021121413563052400_ref4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control\u00a0?","volume":"5","author":"Peeling","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"2021121413563052400_ref5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/1469-0691.12556","article-title":"Leishmaniasis in immunosuppressed individuals","volume":"20","author":"Griensven","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2021121413563052400_ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jtm\/taz055","article-title":"Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis","volume":"26","author":"Boggild","year":"2019","journal-title":"J Travel Med"},{"key":"2021121413563052400_ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jtm\/taaa161","article-title":"Cutaneous leishmaniasis in refugees from Syria: complex cases in berlin 2015 \u2013 2020","author":"Lindner","year":"2020","journal-title":"J Travel Med"},{"key":"2021121413563052400_ref8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s12879-018-3394-0","article-title":"Double trouble: visceral leishmaniasis in twins after traveling to Tuscany \u2013 a case report","volume":"18","author":"Adamczick","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2021121413563052400_ref9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","article-title":"Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of America (IDSA) and the American society of tropical medicine and hygiene (ASTMH)","volume":"96","author":"Aronson","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1590\/0037-8682-0398-2017","article-title":"Combination therapy with liposomal amphotericin b (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case","volume":"51","author":"Ferreira Gomes","year":"2018","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021121413563052400_ref11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1590\/abd1806-4841.20131885","article-title":"Recurrent cutaneous leishmaniasis","volume":"88","author":"Gomes","year":"2013","journal-title":"An Bras Dermatol"},{"key":"2021121413563052400_ref12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/cid\/cix807","article-title":"Long-term clinical outcomes in visceral leishmaniasis\/human immunodeficiency virus \u2013 coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial","volume":"66","author":"Diro","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021121413563052400_ref13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007132","article-title":"Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia","volume":"13","author":"Diro","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2021121413563052400_ref14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021121413563052400_ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tmaid.2018.02.010","article-title":"Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure","author":"Christen","year":"2018","journal-title":"Travel Med Infect Dis"},{"key":"2021121413563052400_ref16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1590\/0074-02760150128","article-title":"Leishmania (Viannia) naiffi: rare enough to be neglected\u00a0?","volume":"110","author":"Fagundes-silva","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2021121413563052400_ref17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/j.1468-3083.2009.03238.x","article-title":"Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil","volume":"23","author":"Amato","year":"2009","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"2021121413563052400_ref18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1179\/136485906x105561","article-title":"Comparison between one and two injections of pentamidine isethionate, at 7 mg\/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana","volume":"100","author":"Roussel","year":"2006","journal-title":"Ann Trop Med Parasitol"},{"key":"2021121413563052400_ref19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-4632.2004.01991.x","article-title":"Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases","volume":"43","author":"El Hajj","year":"2004","journal-title":"Int J Dermatol"},{"key":"2021121413563052400_ref20","first-page":"587","article-title":"Clinical and diagnostic aspects of American tegumentary leishmaniosis in soldiers simultaneously exposed to the infection in the Amazon Region","volume":"36","author":"De Oliveira Guerra","year":"2003","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021121413563052400_ref21","first-page":"35","article-title":"Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate","volume":"63","author":"Lightburn","year":"2003","journal-title":"Med Trop"},{"key":"2021121413563052400_ref22","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1046\/j.1365-4362.2002.01633.x","article-title":"Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam","volume":"41","author":"Lai","year":"2002","journal-title":"Int J Dermatol"},{"key":"2021121413563052400_ref23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/00034983.2001.11813645","article-title":"Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana","volume":"95","author":"Nacher","year":"2001","journal-title":"Ann Trop Med Parasitol"},{"key":"2021121413563052400_ref24","first-page":"1","article-title":"An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region","volume":"2","author":"Gadelha","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2021121413563052400_ref25","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4269\/ajtmh.18-0183","article-title":"Miltefosine combined with Intralesional Pentamidine for Leishmania braziliensis cutaneous leishmaniasis in Bolivia","volume":"99","author":"Soto","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciy619","article-title":"Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis cutaneous leishmaniasis: a randomized, placebo-controlled trial","volume":"68","author":"Soto","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021121413563052400_ref27","doi-asserted-by":"publisher","first-page":"852","DOI":"10.4269\/ajtmh.15-0640","article-title":"Intralesional Pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis","volume":"94","author":"Soto","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1590\/abd1806-4841.20153956","article-title":"Efficacy and safety of a single dose pentamidine (7mg\/kg) for patients with cutaneous leishmaniasis caused by L. guyanensis: a pilot study","volume":"90","author":"Gadelha","year":"2015","journal-title":"An Bras Dermatol"},{"key":"2021121413563052400_ref29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/ced.12786","article-title":"Monitoring the response of patients with cutaneous leishmaniasis to treatment with pentamidine isethionate by quantitative real-time PCR, and identification of Leishmania parasites not responding to therapy","volume":"41","author":"Mans","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"2021121413563052400_ref30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-4632.2009.03883.x","article-title":"Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname","volume":"48","author":"Van Der Meide","year":"2009","journal-title":"Int J Dermatol"},{"key":"2021121413563052400_ref31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1086\/596508","article-title":"In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment","volume":"199","author":"Bourreau","year":"2009","journal-title":"J Infect Dis"},{"key":"2021121413563052400_ref32","first-page":"1","article-title":"Efficacy and tolerance of pentamidine for treatment of cutaneous leishmaniasis caused by por L. (V) Panamensis in Colombia","volume":"26","author":"Robledo","year":"2006","journal-title":"Biomedica"},{"key":"2021121413563052400_ref33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4269\/ajtmh.2005.72.133","article-title":"Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis","volume":"72","author":"Andersen","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref34","first-page":"365","article-title":"A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV\/day for 20 days to treat cutaneous leishmaniasis","volume":"36","author":"D\u00e9 Paula","year":"2003","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021121413563052400_ref35","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1086\/324665","article-title":"High Intralesional Interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment","volume":"184","author":"Bourreau","year":"2001","journal-title":"J Infect Dis"},{"key":"2021121413563052400_ref36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1590\/S0037-86821996000500007","article-title":"Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis","volume":"29","author":"Correia","year":"2019","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021121413563052400_ref37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4269\/ajtmh.1994.50.107","article-title":"Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine","volume":"50","author":"Soto","year":"1994","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/clind\/16.3.417","article-title":"Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia","volume":"16","author":"Soto-mancipe","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2021121413563052400_ref39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0003592","article-title":"Randomized single-blinded non-inferiority trial of 7 mg\/kg pentamidine isethionate versus 4 mg\/kg pentamidine isethionate for cutaneous leishmaniaisis in Suriname","author":"Hu","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2021121413563052400_ref40","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1590\/S0365-05962011000600005","article-title":"A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cuta","volume":"86","author":"Neves","year":"2011","journal-title":"An Bras Dermatol"},{"key":"2021121413563052400_ref41","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1590\/0037-8682-0236-2018","article-title":"Good response to pentamidine isethionate in a case of mucosal leishmaniasis caused by that was difficult to treat: case report","author":"Ferreira Terceiro","year":"2019","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021121413563052400_ref42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1590\/S1678-9946201658020","article-title":"American cutaneous leishmaniasis with unusual clinical presentation and response to treatment","volume":"58","author":"Fernandes","year":"2016","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"2021121413563052400_ref43","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1590\/abd1806-4841.20143073","article-title":"American tegumentary leishmaniasis - a case of therapeutic challenge","volume":"89","author":"Couto","year":"2014","journal-title":"An Bras Dermatol"},{"key":"2021121413563052400_ref44","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/jtm.12065","article-title":"Cluster of zoonotic cutaneous leishmaniasis (Leishmania major) in European travelers returning from Turkmenistan","volume":"20","author":"Larr\u00e9ch\u00e9","year":"2013","journal-title":"J Travel Med"},{"key":"2021121413563052400_ref45","doi-asserted-by":"publisher","first-page":"825","DOI":"10.4269\/ajtmh.2012.11-0728","article-title":"First case of cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in Suriname","volume":"86","author":"Hu","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1590\/S0037-86822011000200026","article-title":"American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report","volume":"44","author":"Pimentel","year":"2011","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021121413563052400_ref47","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2340\/00015555-0893","article-title":"Cutaneous lymphoid hyperplasia associated with Leishmania panamensis infection","volume":"3","author":"Recalcati","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"2021121413563052400_ref48","doi-asserted-by":"publisher","first-page":"588","DOI":"10.4269\/ajtmh.2010.09-0360","article-title":"First cases of cutaneous leishmaniasis caused by Leishmania (Viannia) naiffi infection in Surinam","volume":"82","author":"Thiel","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref49","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1086\/504430","article-title":"Efficacy of short-course intramuscular pentamidine isethionate treatment on old world localized cutaneous leishmaniasis in 2 patients","volume":"42","author":"Jaur\u00e9guiberry","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2021121413563052400_ref50","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4269\/ajtmh.2004.71.558","article-title":"Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions","volume":"71","author":"Couppi\u00e9","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref51","first-page":"653","article-title":"Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report","volume":"13","author":"Calza","year":"2001","journal-title":"J Chem"},{"key":"2021121413563052400_ref52","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1365-3156.1999.00491.x","article-title":"Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome","volume":"4","author":"Salaiza-suazo","year":"1999","journal-title":"Trop Med Int Health"},{"key":"2021121413563052400_ref53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s004360050529","article-title":"The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis","volume":"85","author":"Becker","year":"1999","journal-title":"Parasitol Res"},{"key":"2021121413563052400_ref54","first-page":"268","article-title":"Disseminated cutaneous leishmaniasis revealing human immunodeficiency virus infection","volume":"125","author":"Durand","year":"1998","journal-title":"Ann Dermatol Venereol"},{"key":"2021121413563052400_ref55","first-page":"341","article-title":"Leishmania (Viannia) braziliensis Vianna, 1911 in French Guiana. Clinical, therapeutic and epidemiological considerations in the ninth human diagnosed case","volume":"89","author":"Raccurt","year":"1995","journal-title":"Bull Soc Pathol Exot"},{"key":"2021121413563052400_ref56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1590\/S0037-86821995000400015","article-title":"Diabetes mellitus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis","volume":"28","author":"Costa","year":"1995","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021121413563052400_ref57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-4362.1989.tb04817.x","article-title":"Disseminated cutaneous leishmaniasis","volume":"28","author":"Sharma","year":"1989","journal-title":"Int J Dermatol"},{"key":"2021121413563052400_ref58","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1590\/S0037-86822002000600017","article-title":"American cutaneous leishmaniasis associated with HIV\/AIDS: report of four clinical cases","volume":"35","author":"Sampaio","year":"2002","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021121413563052400_ref59","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3201\/eid1309.061446","article-title":"Recurrent American cutaneous leishmaniasis","volume":"13","author":"Gangneux","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"2021121413563052400_ref60","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1365-2133.2004.06226.x","article-title":"Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV) -infected patients and non-HIV-infected patients in French Guiana","author":"Couppi\u00e9","year":"2004","journal-title":"Br J Dermatol"},{"key":"2021121413563052400_ref61","first-page":"297","article-title":"Epidemics of cutaneous leishmaniasis in military personnel working in French Guiana","volume":"60","author":"Banzet","year":"2000","journal-title":"Med Trop"},{"key":"2021121413563052400_ref62","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1590\/S0037-86821999000500009","article-title":"American cutaneous leishmaniasis in the federal district","volume":"32","author":"Sampaio","year":"1999","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021121413563052400_ref63","first-page":"120","article-title":"Treatment of old world cutaneous leishmaniasis by pentamidine","volume":"5","author":"Hellier","year":"2002","journal-title":"Dermatology"},{"key":"2021121413563052400_ref64","first-page":"492","article-title":"Treatment of mucocutaneous leishmaniasis with pentamidine isothionate","volume":"125","author":"Amato","year":"1998","journal-title":"Ann Dermatol Venereol"},{"key":"2021121413563052400_ref65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1590\/S0036-46651998000100006","article-title":"An evaluation of clinical, serologic, anatomopathologic and immunohistochemical findings for fifteen patients with mucosal leishmaniasis before and after treatment","volume":"40","author":"Amato","year":"1998","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"2021121413563052400_ref66","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1590\/S0037-86821996000500011","article-title":"Treatment of american cutaneous leishmaniasis, with lesions in the mucosa, using pentamidine isethionate","volume":"29","author":"Amato","year":"1996","journal-title":"Rev Soc Bras Med Trop"},{"key":"2021121413563052400_ref67","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/0035-9203(78)90173-6","article-title":"Wheate H. a form of muco-cutaneous leishmaniasis in the old world","volume":"72","author":"Barnetson","year":"1978","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021121413563052400_ref68","article-title":"Treatment of kala-azar with pentamidine isothionate; a study of 55 cases","author":"Hazarika","year":"1949","journal-title":"Ind Med Gaz"},{"key":"2021121413563052400_ref69","first-page":"160","article-title":"Preliminary observations on the treatment of Chinese kala-azar with pentamidine isothionate","volume":"69","author":"LEE","year":"1951","journal-title":"Chin Med J (Engl)"},{"key":"2021121413563052400_ref70","first-page":"314","article-title":"Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial","volume":"39","author":"Jha","year":"1991","journal-title":"J Assoc Physicians India"},{"key":"2021121413563052400_ref71","first-page":"688","article-title":"Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B","volume":"42","author":"Giri","year":"1994","journal-title":"J Assoc Physicians India"},{"key":"2021121413563052400_ref72","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0035-9203(83)90058-5","article-title":"Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India","volume":"77","author":"Jha","year":"1983","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021121413563052400_ref73","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4269\/ajtmh.1991.45.435","article-title":"Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study","volume":"45","author":"Thakur","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref74","first-page":"15","article-title":"Observations on the effect of verapamil with sodium stibogluconate in kala azar","volume":"44","author":"Thakur","year":"1992","journal-title":"Trop Geogr Med"},{"key":"2021121413563052400_ref75","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/0140-6736(92)92952-C","article-title":"Amphotericin versus pentamidine in antimony-unresponsive kala-azar","volume":"340","author":"Mishra","year":"1992","journal-title":"Lancet"},{"key":"2021121413563052400_ref76","first-page":"609","article-title":"A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis","volume":"49","author":"Das","year":"2001","journal-title":"J Assoc Physicians India"},{"key":"2021121413563052400_ref77","first-page":"117","article-title":"A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India","volume":"5","author":"Das","year":"2009","journal-title":"Ther Clin Risk Man"},{"key":"2021121413563052400_ref78","first-page":"543","article-title":"Kala-azar: unresponsiveness to prolonged sodium stibogluconate therapy","volume":"35","author":"Bhattacharya","year":"1987","journal-title":"J Assoc Physicians India"},{"key":"2021121413563052400_ref79","first-page":"119","article-title":"Cutaneo-visceral leishmaniasis: a new opportunistic infection in patients infected by HIV","volume":"18","author":"Botella","year":"2019","journal-title":"Med Cutan Ibero Lat Am"},{"key":"2021121413563052400_ref80","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/BF01744270","article-title":"Visceral leishmaniasis in an HIV-infected patient: clinical features and response to treatment","volume":"69","author":"Fenske","year":"1991","journal-title":"Klin Wochenschr"},{"key":"2021121413563052400_ref81","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00002030-199202000-00020","article-title":"Visceral leishmaniasis and HIV infection: unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis","volume":"6","author":"Matheron","year":"1992","journal-title":"AIDS"},{"key":"2021121413563052400_ref82","first-page":"237","article-title":"Visceral leishmaniasis in an infant in Brittany: discussion on the modes of transmission out endemic zones","volume":"48","author":"Mauny","year":"1993","journal-title":"Pediatrie"},{"key":"2021121413563052400_ref83","first-page":"543","article-title":"Visceral leishmaniasis and HIV infection: the diagnostic and therapeutic problems","volume":"6","author":"Rocha","year":"1993","journal-title":"Acta Med Trop"},{"key":"2021121413563052400_ref84","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0035-9203(94)90309-3","article-title":"Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B","volume":"88","author":"Gokhale","year":"1994","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021121413563052400_ref85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0163-4453(95)80012-3","article-title":"Asymptomatic visceral leishmaniasis in a child with acute lymphoblastic leukaemia","volume":"30","author":"Mehrotra","year":"1995","journal-title":"J Infect"},{"key":"2021121413563052400_ref86","first-page":"39","article-title":"A case of kala-azar diagnosed by bone marrow aspiration","volume":"17","author":"Hamidah","year":"1995","journal-title":"Malays J Pathol"},{"key":"2021121413563052400_ref87","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0300-2977(94)00109-M","article-title":"Treatment of visceral leishmaniasis in a patient with AIDS with antimony and y-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine","volume":"47","author":"Lustig","year":"1995","journal-title":"Neth J Med"},{"key":"2021121413563052400_ref88","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0929-693X(96)84691-4","article-title":"Resistance of Leishmania infantum to glucantime: risk factors and therapeutic management","volume":"3","author":"Piarroux","year":"1996","journal-title":"Arch Pediatr"},{"key":"2021121413563052400_ref89","first-page":"713","article-title":"A case report of visceral leishmaniasis in Singapore","volume":"26","author":"Abraham","year":"1997","journal-title":"Ann Acad Med Singapore"},{"key":"2021121413563052400_ref90","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/j.1365-2133.2007.08157.x","article-title":"Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome","volume":"157","author":"Antinori","year":"2007","journal-title":"Br J Dermatol"},{"key":"2021121413563052400_ref91","first-page":"339","article-title":"Diffuse skin spread of HIV-associated visceral leishmaniasis: cumbersome diagnostic and therapeutic issues","volume":"143","author":"Manfredi","year":"2008","journal-title":"G Ital Dermatol Venereol"},{"key":"2021121413563052400_ref92","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.ijid.2008.08.011","article-title":"Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis","volume":"13","author":"Makaritsis","year":"2009","journal-title":"Int J Infect Dis"},{"key":"2021121413563052400_ref93","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.eimc.2008.11.022","article-title":"Raised tattoos in a human immunodeficiency virus-infected patient","volume":"27","author":"Garc\u00eda-L\u00e1zaro","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2021121413563052400_ref94","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ijid.2009.06.010","article-title":"Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure \u2014 a case report and brief review of the literature","volume":"14","author":"Rybniker","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2021121413563052400_ref95","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1155\/2012\/787305","article-title":"Challenges in the management of Leishmania\/HIV coinfection in a nonendemic area: a case report","volume":"2012","author":"Grabmeier-Pfistershammer","year":"2012","journal-title":"Case Rep Infect Dis"},{"key":"2021121413563052400_ref96","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.parint.2016.06.009","article-title":"Serial use of pentamidine and miltefosine for treating Leishmania infantum -HIV coinfection","volume":"65","author":"Faucher","year":"2016","journal-title":"Parasitol Int"},{"key":"2021121413563052400_ref97","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/ccr3.1266","article-title":"Visceral leishmaniasis triggering an adult-onset Still\u2019s disease: a unique case","volume":"5","author":"Spoto","year":"2017","journal-title":"Clin Case Rep"},{"key":"2021121413563052400_ref98","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0035-9203(85)90199-3","article-title":"Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine","volume":"79","author":"Bryceson","year":"1985","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021121413563052400_ref99","first-page":"255","article-title":"Clinicoepidemiological profile of kala azar patients in Delhi","volume":"21","author":"Mittal","year":"1989","journal-title":"J Commun Dis"},{"key":"2021121413563052400_ref100","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0377-1237(01)80128-3","article-title":"Problems in management of kala azar: experience from Bihar","volume":"57","author":"Rai","year":"2001","journal-title":"Med J Armed Forces India"},{"key":"2021121413563052400_ref101","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.trstmh.2009.02.023","article-title":"Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns","volume":"103","author":"Padovese","year":"2009","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021121413563052400_ref102","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1128\/CMR.00080-14","article-title":"Visceral leishmaniasis in China: an endemic disease under control","volume":"28","author":"Lun","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2021121413563052400_ref103","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/clinids\/7.5.625","article-title":"Pentamidine: a review","volume":"7","author":"Sands","year":"1985","journal-title":"Rev Infect Dis"},{"key":"2021121413563052400_ref104","volume-title":"Drugs","author":"WHO","year":"2016"},{"key":"2021121413563052400_ref105","volume-title":"Foye\u2019s Principles of Medicinal Chemistry","author":"Lemke","year":"2013","edition":"Seventh"},{"key":"2021121413563052400_ref106","volume-title":"Manual on case managment and surveillance of the leishmaniases in the WHO European Region","author":"Gradoni","year":"2017"},{"key":"2021121413563052400_ref107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004495","article-title":"Treatment of cutaneous leishmaniasis caused by Leishmania aethiopica: a systematic review","volume":"10","author":"Van","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2021121413563052400_ref108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061843","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update","volume":"8","author":"Nicholls","year":"2013","journal-title":"PLoS One"},{"key":"2021121413563052400_ref109","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/infdis\/165.3.528","article-title":"Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala","volume":"165","author":"Navin","year":"1992","journal-title":"J Infect Dis"},{"key":"2021121413563052400_ref110","doi-asserted-by":"crossref","first-page":"960","DOI":"10.4269\/ajtmh.1999.61.960","article-title":"Response of cutaneous leishmaniasis (chiclero\u2019s ulcer) to treatment with meglumine antimoniate in Southeast Mexico","volume":"61","author":"Vargas-gonzalez","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref111","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0035-9203(91)90437-4","article-title":"Cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis Amazonian Brazil, and the significance of a negative Montenegro skin-test human infections in in human infections","volume":"85","author":"Silveira","year":"1991","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021121413563052400_ref112","doi-asserted-by":"crossref","first-page":"934","DOI":"10.7326\/0003-4819-113-12-934","article-title":"Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis","volume":"113","author":"Franke","year":"1990","journal-title":"Ann Intern Med"},{"key":"2021121413563052400_ref113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002832","article-title":"Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide","volume":"8","author":"Hodiamont","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2021121413563052400_ref114","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/clinids\/24.2.165","article-title":"Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate","volume":"24","author":"Martinez","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2021121413563052400_ref115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-4632.2008.03417.x","article-title":"Treatment of new world cutaneous leishmaniasis \u2013 a systematic review with a meta-analysis","author":"Tuon","year":"2008","journal-title":"Int J Dermatol"},{"key":"2021121413563052400_ref116","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/383321","article-title":"Miltefosine for new world cutaneous leishmaniasis","volume":"38","author":"Soto","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2021121413563052400_ref117","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-talhari","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref118","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4269\/ajtmh.2010.10-0060","article-title":"Efficacy of Miltefosine for the treatment of American cutaneous leishmaniasis","volume":"83","author":"V\u00e9lez","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2021121413563052400_ref119","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jaad.2012.06.014","article-title":"Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am","volume":"68","author":"Solomon","year":"2012","journal-title":"Dermatology"},{"key":"2021121413563052400_ref120","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/trstmh\/tru011","article-title":"Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients","volume":"108","author":"Rocio","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021121413563052400_ref121","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cmi.2017.11.008","article-title":"Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies","volume":"24","author":"Rodrigo","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2021121413563052400_ref122","volume-title":"(DF). Manual de Vigil\u00e2ncia Da Leishmaniose Tegumentar Americana","author":"Minist\u00e9rio da Sa\u00fade","year":"2010","edition":"3rd"},{"key":"2021121413563052400_ref123","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the new world","volume":"118","author":"Oliveira","year":"2011","journal-title":"Acta Trop"},{"key":"2021121413563052400_ref124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0004363","article-title":"Efficacy and safety of Pafuramidine versus Pentamidine maleate for treatment of first stage sleeping sickness in a randomized , comparator-controlled, international phase 3 clinical trial","volume":"10","author":"Pohlig","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2021121413563052400_ref125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0004362","article-title":"Efficacy, safety, and dose of pafuramidine, a new oral drug for treatment of first stage sleeping sickness, in a phase 2a clinical study and phase 2b randomized clinical studies","author":"Burri","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2021121413563052400_ref126","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/jtm.12089","article-title":"LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014","volume":"21","author":"Blum","year":"2014","journal-title":"J Travel Med"},{"key":"2021121413563052400_ref127","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijid.2020.06.003","article-title":"Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine , oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate","volume":"97","author":"Basile","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2021121413563052400_ref128","volume-title":"Leishmaniasis in the Americas. Recommendations for the treatment","author":"PAHO","year":"2018"},{"key":"2021121413563052400_ref129","article-title":"Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America","author":""}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taab065\/37910956\/taab065.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/28\/6\/taab065\/41748607\/taab065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/28\/6\/taab065\/41748607\/taab065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T08:58:52Z","timestamp":1639472332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taab065\/6246322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":129,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,22]]},"published-print":{"date-parts":[[2021,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taab065","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,4,22]]},"article-number":"taab065"}}